Addiction, anxiety and Alzheimer's disease tackled by new Chair at Imperial College
A leading researcher who looks at how the brain behaves in people with health problems such as addiction, anxiety and Alzheimer's disease has been announced today as the new Edmond J Safra Chair in Neuropsychopharmacology at Imperial College London. Professor David Nutt will be using cutting-edge scanning techniques to develop new treatments for a range of conditions, including Alzheimer's disease and depression.
(Media-Newswire.com) - A leading researcher who looks at how the brain behaves in people with health problems such as addiction, anxiety and Alzheimer’s disease has been announced today as the new Edmond J Safra Chair in Neuropsychopharmacology at Imperial College London.
Professor David Nutt will be using cutting-edge scanning techniques to develop new treatments for a range of conditions, including Alzheimer’s disease and depression.
An expert in how the circuits in the brain work together, Professor Nutt has made key discoveries about the role of neurotransmitters in anxiety, depression, addiction and sleep that have improved the treatment of patients with these disorders.
The Edmond J Safra Chair in Neuropsychopharmacology is a new position at Imperial, established with a donation from the Edmond J Safra Philanthropic Foundation and Mrs Lily Safra.
In addition to his new chair, Professor Nutt will also lead a new Department of Neuropsychopharmacology and Molecular Imaging at the College, which will be launched early in 2009. The Department is being funded jointly by Imperial College London and the Central and North West London ( CNWL ) NHS Foundation Trust.
In his research, Professor Nutt hopes to develop existing Positron Emission Tomography ( PET ) scanning techniques to explore the different receptors in the brain involved in conditions such as addiction and anxiety.
Professor Nutt, from the Division of Neuroscience and Mental Health at Imperial College London said: “I want to explore further what happens in the brain in conditions like anxiety and depression. In the long term, I would like to properly understand the brain circuits that underlie these conditions with a view to developing new treatments. I would like to see new treatments in pilot studies within the next five years.”
“Another condition I want to explore is Alzheimer’s disease and one of the first things I’ll be working on at Imperial is developing new PET tracers to study this condition. For a long time, scientists have been looking at amyloid proteins that form plaques in the brains of patients with Alzheimer’s disease. However, the condition is still poorly understood and I would like to look into different factors, including the role that inflammation might play in the brain,” added Professor Nutt.
Researchers use PET scanning to build up a picture of the brain, to see what is happening in conditions such as Alzheimer’s disease and depression. PET scanners can reveal which parts of the brain are working, show if there are too few or too many receptors in the brain and can be used to measure the amount of proteins. For example, in 2006, researchers at Imperial devised a new technique that enabled them to see the amyloid proteins that build up in the brains of patients with Alzheimer’s disease. They made amyloid proteins visible in a PET scan by attaching a radioactive dye to a molecule that binds to the amyloid protein. This meant they could identify people who were likely to develop Alzheimer’s disease.
Previous research by Professor Nutt has shown that there are faults in the main system in the brain that inhibits signals in patients with severe anxiety and in alcoholics. He also discovered that alcoholic patients had a similar increase in endorphin receptors in the brain to those addicted to heroin, suggesting that this may be a common factor to different forms of addiction. Professor Nutt created the first PET tracers to see the brain receptors involved in anxiety and showed that antidepressants can be used to treat panic and social anxiety disorder.
Professor Lefkos Middleton, head of the Division of Neuroscience and Mental Health at Imperial College London, said: “addiction and substance abuse are increasing public health problems in the UK and we have yet to find effective ways of treating them. We are excited to welcome Professor Nutt to Imperial and the Central and North West London NHS Foundation Trust, where we are confident he will use his expert knowledge and experience to develop new treatments for health problems such as these, which will make a real difference to patients’ lives.”
Lily Safra, Chairwoman of the Edmond J. Safra Foundation said: "We are absolutely delighted that David Nutt, a visionary scholar, will be the first occupant of the Edmond J. Safra Chair. His research provides hope to so many people suffering from diseases that we have barely begun to understand, and we wish him and his team much success."
Professor Nutt joins Imperial from the University of Bristol, where he was Professor of Psychopharmacology and Director of the Psychopharmacology Unit. He has recently been appointed Chair of the Home Office’s Advisory Council on the Misuse of Drugs. He is currently working with the MRC on national strategies for addiction research and PET imaging as a member of the Neuroscience and Mental Health Board.
-ENDS-
Release Date
This story was released on 2009-01-09. Please make sure to visit the official company or organization web site to learn more about the original release date. See our disclaimer for additional information.
